Literature DB >> 9111487

Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children.

A Des Roches1, L Paradis, J L Menardo, S Bouges, J P Daurés, J Bousquet.   

Abstract

BACKGROUND: The natural history of allergic sensitization is complex and poorly understood. A prospective nonrandomized study was carried out in a population of asthmatic children younger than 6 years of age whose only allergic sensitivity was to house dust mites (HDMs).
OBJECTIVES: The study was designed to determine whether specific immunotherapy (SIT) with standardized allergen extracts could prevent the development of new sensitizations over a 3-year follow-up survey.
METHODS: We studied 22 children monosensitized to HDM who were receiving SIT with standardized allergen extracts and 22 other age-matched control subjects who were monosensitized to HDM. The initial investigation included a full clinical history, skin tests with a panel of standardized allergens, and the measurement of allergen-specific IgE, depending on the results of skin tests. Children were followed up on an annual basis for 3 years, and the development of new sensitizations in each group was recorded.
RESULTS: Ten of 22 children monosensitized to HDM who were receiving SIT did not have new sensitivities compared with zero of 22 children in the control group (p = 0.001, chi square test).
CONCLUSIONS: This study suggests that SIT in children monosensitized to HDM alters the natural course of allergy in preventing the development of new sensitizations.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9111487     DOI: 10.1016/s0091-6749(97)70069-1

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  73 in total

Review 1.  Allergic rhinitis/asthma interrelationships.

Authors:  T B Casale; B V Amin
Journal:  Clin Rev Allergy Immunol       Date:  2001-08       Impact factor: 8.667

Review 2.  Allergen immunotherapy.

Authors:  R E Esch; J Portnoy
Journal:  Curr Allergy Asthma Rep       Date:  2001-11       Impact factor: 4.806

Review 3.  Allergen exposure and the development of asthma.

Authors:  R Sporik; T A Platts-Mills
Journal:  Thorax       Date:  2001-09       Impact factor: 9.139

Review 4.  Will sublingual immunotherapy offer benefit for asthma?

Authors:  Carlos E Baena-Cagnani; Désirée Larenas-Linnemann; Alvaro Teijeiro; Giorgio Walter Canonica; Giovanni Passalacqua
Journal:  Curr Allergy Asthma Rep       Date:  2013-12       Impact factor: 4.806

5.  Safety and tolerability of an SQ-standardized GRAss ALlergy immunotherapy tablet (GRAZAX®) in a real-life setting for three consecutive seasons - the GRAAL trial.

Authors:  François Wessel; Antoine Chartier; Jean-Pierre Meunier; Antoine Magnan
Journal:  Clin Drug Investig       Date:  2012-07-01       Impact factor: 2.859

Review 6.  Immunotherapy in the age of anti-IgE.

Authors:  Ira Finegold
Journal:  Clin Rev Allergy Immunol       Date:  2004-10       Impact factor: 8.667

Review 7.  Sublingual immunotherapy in pediatric allergic rhinitis and asthma: efficacy, safety, and practical considerations.

Authors:  Linda Cox
Journal:  Curr Allergy Asthma Rep       Date:  2007-11       Impact factor: 4.806

8.  Differential regulation of IL-4Ralpha expression by antigen versus cytokine stimulation characterizes Th2 progression in vivo.

Authors:  Georgia Perona-Wright; Katja Mohrs; Katrin D Mayer; Markus Mohrs
Journal:  J Immunol       Date:  2009-12-16       Impact factor: 5.422

Review 9.  Clinical Immunology Review Series: An approach to the patient with allergy in childhood.

Authors:  R Sporik; J Henderson; J O'B Hourihane
Journal:  Clin Exp Immunol       Date:  2009-03       Impact factor: 4.330

Review 10.  Allergic rhinitis in children : diagnosis and management strategies.

Authors:  William E Berger
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.